 | • レポートコード：MRC2303B100 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の脊髄性筋萎縮症（SMA）治療市場規模が予測期間中に年平均14.5％上昇すると推測されています。本調査書では、脊髄性筋萎縮症（SMA）治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（1型、2型、3型、4型）分析、処置別（遺伝子置換療法、薬物療法、その他）分析、投与経路別（経口、髄腔内注入）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Novartis International AG、Biogen Inc.、Cytokinetics Inc.、F. Hoffmann - La Roche Ltd、Pfizer Inc.、Isis Pharmaceuticals Inc.、Sanofi Aventis Inc. (GenZyme Corporation)、Avexis Inc.、Catalyst Pharmaceutical、Chugai Pharmaceuticalなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：種類別 - 1型脊髄性筋萎縮症（SMA）治療の市場規模 - 2型脊髄性筋萎縮症（SMA）治療の市場規模 - 3型脊髄性筋萎縮症（SMA）治療の市場規模 - 4型脊髄性筋萎縮症（SMA）治療の市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：処置別 - 遺伝子置換療法における市場規模 - 薬物療法における市場規模 - その他処置における市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：投与経路別 - 経口型脊髄性筋萎縮症（SMA）治療の市場規模 - 髄腔内注入型脊髄性筋萎縮症（SMA）治療の市場規模 ・世界の脊髄性筋萎縮症（SMA）治療市場規模：地域別 - 北米の脊髄性筋萎縮症（SMA）治療市場規模 アメリカの脊髄性筋萎縮症（SMA）治療市場規模 カナダの脊髄性筋萎縮症（SMA）治療市場規模 メキシコの脊髄性筋萎縮症（SMA）治療市場規模 … - ヨーロッパの脊髄性筋萎縮症（SMA）治療市場規模 ドイツの脊髄性筋萎縮症（SMA）治療市場規模 イギリスの脊髄性筋萎縮症（SMA）治療市場規模 フランスの脊髄性筋萎縮症（SMA）治療市場規模 … - アジア太平洋の脊髄性筋萎縮症（SMA）治療市場規模 中国の脊髄性筋萎縮症（SMA）治療市場規模 日本の脊髄性筋萎縮症（SMA）治療市場規模 インドの脊髄性筋萎縮症（SMA）治療市場規模 … - 南米/中東の脊髄性筋萎縮症（SMA）治療市場規模 南アフリカの脊髄性筋萎縮症（SMA）治療市場規模 ブラジルの脊髄性筋萎縮症（SMA）治療市場規模 アルゼンチンの脊髄性筋萎縮症（SMA）治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The spinal muscular atrophy treatment market is expected to register a CAGR of 14.5% during the forecast period.
Due to strict lockdown measures and restricted movement of people, the COVID-19 virus outbreak has had a significant impact on the spinal muscular atrophy medicine industry. The unprecedented coronavirus outbreak (SARS-CoV-2) has cast a shadow over the SMA treatment industry. For instance, according to the article published in the National Institute of Health in May 2020, titled “Spinal muscular atrophy care in the COVID‐19 pandemic era,” the delay in the SMA treatment during the pandemic affected the delivery of clinical care to patients with spinal muscular atrophy (SMA). Moreover, the amount of money available for the R&D and drug development for SMA has been decreasing, as the majority of the money has been spent on COVID-19 vaccine production.
The major factors accounting for the growth of the spinal muscular atrophy treatment market are growing awareness regarding SMA, its diagnosis and treatment, rise in the government initiatives to improve healthcare infrastructure, and increasing R&D activities to develop novel treatment regimens. For instance, in August 2020, the US Food and Drug Administration approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease. Emerging treatment therapies in the treatment of SMA are driving the growth of the market during the forecast period.
However, the high cost of treatment and lack of skilled professionals for surgical procedures and physiotherapy regimens hampers the market to some extent.
Spinal Muscular Atrophy Treatment Market Trends
The Gene Replacement Therapy Segment Dominates the Market, and the Same is Expected Over the Forecast Period
Gene replacement therapy is the technique of recognizing a faulty gene, applying a piece of DNA in its correct form through a viral vector (known as the carrier molecule) to the gene, thus, overriding the identified faulty gene with the correct copy.
Gene replacement therapy is expected to dominate the spinal muscular atrophy treatment market over the forecast period, attributing to its advantages over the disadvantages. However, investment in research and development activities is also expected to have a significant effect on the segment. Companies such as Pfizer Inc. are aiming to build a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, and potential licensing and merger and acquisition activities. For instance, in August 2019, Pfizer was investing USD 500 million to expand a manufacturing facility in North Carolina, which plays a central role in its efforts to become a major player in the gene therapy industry.
The effects of gene replacement therapy are long-lasting and improve the quality of life by eradicating genetic disorders. Recently in May 2019, the US FDA approved Zolgensma for the treatment of spinal muscular atrophy is a gene therapy, which is found to be the most efficient in results, and many other drugs are in the pipeline. Thus, gene replacement therapy dominates the spinal muscular atrophy treatment market. However, the healthcare cost for gene therapy using Zolgensma is high, but this may hamper the market to a very less extent, as the government is raising huge funds for the treatment of rare diseases. For example, under the government’s Ayushman Bharat scheme in India, the current draft policy provides up to INR 15 lakhs for rare disease treatment to patients who require one-time treatment.
Thus, all aforementioned factors, such as the advantages of gene replacement therapy and technological advancement in gene therapy, may boost the segment over the forecast period.
North America Dominates the Market, and the Same is Expected Over the Forecast Period
North America is expected to dominate the overall market throughout the forecast period, which is attributed to the developed economy, increasing health care expenditure, increasing incidence of lifestyle-related diseases, and high adoption of technologically advanced products in the region. According to the article published by Columbia University in November 2021, more than 7,000 rare diseases affect 25 million to 30 million American children and adults. More than 90% of rare diseases lack a Food and Drug Administration (FDA)-approved treatment. The reimbursement policies in the United States, especially for the treatment of rare diseases, further boost the market in North America.
Moreover, many key players in the market are focused on adopting strategies, such as mergers and acquisitions, to enhance their product portfolio, which, in turn, is expected to propel market growth over the forecast period. For instance, in August 2020, the US Food and Drug Administration approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Thus, North America dominates the spinal muscular atrophy treatment market during the forecast period.
Spinal Muscular Atrophy Treatment Market Competitor Analysis
The spinal muscular atrophy treatment market is moderately competitive and consists of several major players. With the increasing consolidations of various organizations and product recalls in the healthcare sector, it is expected to generate competitive rivalry among the key players in the future. Some of the major players of the market are Novartis AG, Biogen Inc., F. Hoffmann – La Roche Ltd, and Cytokinetics Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness Regarding Spinal Muscular Atrophy, Its Diagnostics, and Its Treatment
4.2.2 Rise in the Government Initiatives to Improve Healthcare Infrastructure
4.2.3 Increasing R&D Activities to Develop Novel Treatment Regimens for Rare Diseases
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Lack of Skilled Professionals for Surgical Procedures and Physiotherapy Regimens
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Type 1
5.1.2 Type 2
5.1.3 Type 3
5.1.4 Type 4
5.2 By Procedure
5.2.1 Gene Replacement Therapy
5.2.2 Drug Therapy
5.2.3 Other Procedures
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Intrathecal
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis International AG
6.1.2 Biogen Inc.
6.1.3 Cytokinetics Inc.
6.1.4 F. Hoffmann – La Roche Ltd
6.1.5 Pfizer Inc.
6.1.6 Isis Pharmaceuticals Inc.
6.1.7 Sanofi Aventis Inc. (GenZyme Corporation)
6.1.8 Avexis Inc.
6.1.9 Catalyst Pharmaceutical
6.1.10 Chugai Pharmaceutical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS